Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases. We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients. Clinical Development Asset Lead Position purpose Adimanebart (ARGX-119) is a novel anti-MuSK (muscle-specific kinase) agonist monoclonal antibody being developed as a pipeline in a product for neuromuscular diseases. argenx is seeking a dynamic clinical development leader to provide expertise across multiple indications, including CMS (congenital myasthenic syndromes), ALS (amyotrophic lateral sclerosis), and SMA (spinal muscular atrophy) clinical programs, while also driving the rapid evaluation of new indications. The candidate will be responsible for delivering strategic clinical development leadership and oversight as part of the Asset Strategy Team (a cross-functional group focused on maximizing asset potential), working closely with other team members and the indication development teams to maximize the value of the asset and the success of the multi-indication program. The ideal candidate will have significant experience in clinical development for neurologic disorders and a proven track record in drug development.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Education Level
Ph.D. or professional degree
Number of Employees
1,001-5,000 employees